The current financial score of Organon & Co is 8.69. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.56B, representing a year-over-year decrease of 2.26%, while its net profit experienced a year-over-year decrease of 25.52%.
The current valuation score of Organon & Co is 9.43. Its current P/E ratio is 14.49, which is 27.55% below the recent high of 18.48 and 83.88% above the recent low of 2.34.
The current earnings forecast score of Organon & Co is 5.67. The average price target is 11.25, with a high of 14.00 and a low of 8.00.
The current price momentum score of Organon & Co is 1.20. Currently, the stock price is trading between the resistance level at 13.77 and the support level at 13.61, making it suitable for range-bound swing trading.
The current institutional shareholding score of Organon & Co is 10.00. The latest institutional shareholding proportion is 91.12%, representing a quarter-over-quarter increase of 17.90%. The largest institutional shareholder is Irving Kahn, holding a total of 5.54M shares, representing 5.88% of shares outstanding, with 27.59% increase in holdings.
The current risk assessment score of Organon & Co is 9.15. The company's beta value is 1.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.